High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity |
Jun 2020 |
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity |
Aug 2020 |
International Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy |
May 2024 |
International Journal of Laboratory Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges |
Aug 2020 |
International Journal of Laboratory Hematology |
Myelodysplastic Syndromes (MDS) |
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria |
May 2023 |
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study |
Dec 2019 |
JAMA Oncology |
Myelodysplastic Syndromes (MDS) |
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
Sep 2019 |
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
Feb 2021 |
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations |
Dec 2023 |
Journal of Blood Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Oct 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |